MetaCap

IDEAYA Biosciences (IDYA) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 109.6% versus a loss of 24.8%. Over five years, IDYA leads with a +7.3% price change compared with -6.2% for XNCR. Xencor is the larger company by market cap ($2.50 billion vs $2.47 billion), about 1.0 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +13.7%).

IDEAYA Biosciences converts more of its revenue into profit, with a net margin of -52.0% versus -73.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%XNCR+109.58%
+161%+59%-44%
Nov 21, 20251 yearNov 20, 2026
IDYA+10.08%XNCR-9.77%
+112%+11%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus XNCR key metrics
MetricIDYAXNCR
Share price$25.56$33.26
Market cap$2.47B$2.50B
1-day change-2.33%-2.21%
YTD return-26.06%+117.24%
1-year return-24.80%+109.58%
5-year return+7.35%-6.15%
EPS (TTM)$-4.50$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M$125.58M
Revenue growth (YoY)+3024.43%+13.65%
Net income (latest FY)$-113.70M$-91.92M
Operating margin-72.84%-141.35%
Net margin-51.99%-73.20%
52-week high$42.68$40.60
52-week low$25.46$10.38
Distance from 52-week high-40.11%-18.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+98.32%+27.78%
Average volume933.58K1.54M
Shares outstanding96.69M75.04M
Employees145260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed IDYA by 134.4 percentage points over the past year.
  • IDEAYA Biosciences is more profitable, keeping -52.0 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
  • IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +13.65%).

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

IDYA vs XNCR FAQ

Which is bigger, IDEAYA Biosciences or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.47B for IDEAYA Biosciences (IDYA).

Which stock has performed better over the past year, IDYA or XNCR?

XNCR returned +109.58% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons